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Tuberculosis (TB) remains an enormous global public health threat, especially in low- and mid-
dle-income countries (LMICs). In 2017, there were an 
estimated 10.0 million incident cases and 1.6 million 
deaths due to TB, making TB one of the top 10 leading 
causes of death worldwide and the leading cause from 
a single infectious agent.1 In 2017, only 6.4 million 
new patients with TB were reported, meaning that 3.6 
million (36% of the estimated disease burden) were ei-
ther not diagnosed or not notified to national pro-
grammes.1 In most LMICs, TB case detection is based 
on passive case finding, but this strategy, as shown in 
many TB prevalence surveys, is inadequate to detect 
the substantial burden of undiagnosed TB in the com-
munity.2 Alternative strategies are needed, and one of 
these is active case finding (ACF), which seeks to 
pro-actively identify patients with TB.
Modelling studies suggest that ACF can increase TB 
case finding, and the World Health Organization 
(WHO) has provided guidelines for systematically and 
actively screening TB contacts and high-risk patient 
groups.3,4 In one review, yields of newly diagnosed TB 
through ACF varied from 0.7% in population-based 
community surveys to over 8% in human immunode-
ficiency virus (HIV) care clinics.5 Prisons and health 
care facilities are especially high-risk areas for trans-
mission of TB,6,7 and ACF in these settings can help to 
identify cases early and reduce ongoing transmission.
Zimbabwe is among the 14 countries in the world 
with a high triple burden of TB, TB-HIV and multi-
drug-resistant TB.1 TB in the country has been fuelled 
by the HIV epidemic, with TB-HIV co-infection rates 
of 63% in 2017.1 In 2017, TB treatment coverage (no-
tified/estimated incidence) was estimated to be 71%,1 
which meant that almost 30% of TB patients were ei-
ther not diagnosed or not registered in the National 
TB Control Programme (NTP), posing a risk for af-
fected individuals and the community due to ongoing 
TB transmission.
Zimbabwe has for many years relied heavily on a 
passive case finding strategy with its many disadvan-
tages. The WHO End TB Strategy, however, endorses 
the early diagnosis of TB, including the systematic and 
active screening of high-risk groups (HRGs).8 In line 
with this global effort towards ending TB, the NTP in 
Zimbabwe, in collaboration with other partner organi-
sations, has adopted various ACF strategies. One of 
these is the use of mobile trucks for targeted active 
screening for TB (Tas4TB), which aims to target HRGs. 
These HRGs comprise the elderly (age 65 years); peo-
ple living with HIV (PLHIV); miners (formal and infor-
mal); prisoners (current and past); healthcare workers; 
refugees; those previously diagnosed with TB; and 
contacts of TB patients.
The Tas4TB Programme has a strong focus on the 
identification of TB cases, with little attention paid to 
further linkage to care and treatment outcomes. This 
is mainly because the Tas4TB screening teams spend 
one day at a site and leave the investigation of persons 
with presumptive TB, the diagnosis of TB and initia-
tion of treatment and subsequent monitoring in the 
hands of the local health facilities. The whole process 
of screening, diagnosis, linkage to care and documen-
tation of treatment outcomes of patients diagnosed 
during Tas4TB has not yet been systematically evalu-
ated, and this information would be valuable for the 
Zimbabwe NTP.
The aim of the present study therefore was to assess 
how Tas4TB performed in Zimbabwe in 2017 in terms 
of diagnosis, linkage to care and treatment outcomes 
in those identified with TB. Specific objectives were to 
determine 1) the numbers and characteristics of those 
Received 12 June 2019
Accepted 1 September 2019
http://dx.doi.org/10.5588/pha.19.0040
Setting: Targeted active screening for tuberculosis 
(Tas4TB) using mobile trucks in the community was im-
plemented in 15 high TB burden districts in Zimbabwe. 
At-risk populations were screened for TB based on symp-
toms and chest radiography (CXR) results. Those with 
any positive symptom and/or an abnormal CXR had spu-
tum collected for investigation and diagnosis and were 
linked to care and treatment if found to have TB.
Objective: To determine 1) the proportion and charac-
teristics of those screened and diagnosed with TB; 2) the 
relationship between TB symptoms, CXR and diagnostic 
yields; and 3) the relationship between initiation of an-
ti-TB treatment and treatment outcomes.
Design: Cohort study using routinely collected data
Results: A total of 39 065 persons were screened, of 
whom 663 (1.7%) were diagnosed with TB; 126/663 
(19.0%) were bacteriologically confirmed. The highest 
TB diagnostic yields were in symptomatic persons with 
CXRs suggestive of TB (19.4%), asymptomatic persons 
with CXRs suggestive of TB (8.4%) and persons at high-
risk of TB (3.2%). For all diagnosed TB patients, pre-treat-
ment loss to follow-up was 18.9% and treatment success 
was 59.9%.
Conclusion: Tas4TB resulted in high diagnostic yields; 
however, linkage of diagnosis to care was poor. Reasons 
for loss to follow-up need to be better understood and 
rectified.
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screened and diagnosed with TB, 2) how the presence 
or absence of TB symptoms and chest radiography 
(CXR) findings related to TB diagnostic yields, and 3) 




This was a cohort study using routinely collected data.
Setting
General setting
Zimbabwe is a land-locked country in southern Africa. 
It has a population of 13 million and a gross domestic 
product per capita of US$1,333.9,10 The country is di-
vided into 10 administrative provinces, covering 63 
health districts. Most health care is delivered through 
primary health care facilities where services at the 
point-of-care are free of charge.
Zimbabwe National TB Control Programme
The NTP is responsible for coordinating national TB 
control efforts. The programme is represented and co-
ordinated at the national level by a central unit, and at 
the provincial and district levels by provincial and dis-
trict TB coordinators, respectively. The diagnosis and 
treatment of TB are provided free of charge at public 
health facilities with other general health services. 
Over the last two decades, the country has been com-
pliant with international TB control policies and has 
adopted the WHO TB guidelines as part of its own na-
tional TB guidelines.11–13
Targeted screening for tuberculosis
The Tas4TB programme was started in 2017 in 15 pri-
ority districts purposively selected based on high bur-
dens of TB. The Tas4TB programme has a medical team 
(comprising nurses, counsellors, radiographers, labora-
tory scientists, medical officers and data officers) and 
uses a mobile X-ray truck to offer free health services 
to the population, including hard-to-reach groups. 
There is also a demand creation team, mostly compris-
ing health promoters, that mobilises communities, 
identifies screening sites and schedules dates.
The team and the truck arrive at a designated site 
and actively screen people who come forward; this in-
cludes those from HRGs (estimated to comprise 12% of 
the population of the 15 priority districts) and non-
HRGs. The screening process involves patient registra-
tion, screening, HIV testing and counselling, and spu-
tum collection for those found to have presumptive 
TB. Screening for each person involves a symp-
tom-based enquiry focused on cough of any duration, 
fever and night sweats, and a digital CXR is also per-
formed; this is read by the medical officer in the team. 
Those with one or more positive symptoms and/or an 
abnormal CXR (suggestive or not suggestive of TB) are 
identified as having presumptive TB and are asked to 
produce one sputum specimen, which is delivered by 
the mobile truck team to the nearest district hospital 
for analysis, usually using the Xpert® MTB/RIF assay 
(Cepheid, Sunnyvale, CA, USA). If Xpert technology is 
not available, sputum specimens are examined using 
direct smear microscopy for acid-fast bacilli. Patients 
with bacteriologically diagnosed TB (Xpert- or sputum 
smear-positive) are referred to the nearest health facil-
ity for registration and initiation of treatment. Those 
with negative sputum specimens are further assessed 
to determine whether they have clinically diagnosed 
TB.
Data are collected using a smart phone android ap-
plication that links with a central electronic database 
in real time. The system runs on an SQL Server back-
end, with built-in validations, and this is used to cap-
ture patient-level data at each stage of the screening 
cascade using smart phones.
Study population
The study includes all persons (including those be-
longing to HRGs) in selected districts that were 
reached and screened for TB by the Tas4TB programme 
in 2017.
Data variables, sources of data and data 
collection
The data variables included demographic data, HRG 
status, HIV status, symptoms at screening, CXR result, 
ACKNOWLEDGEMENTS
This research was conducted 
through the Structured 
Operational Research and 
Training Initiative (SORT IT), 
a global partnership led by 
the Special Programme for 
Research and Training in 
Tropical Diseases at the 
World Health Organization 
(WHO/TDR). The training 
model is based on a course 
developed jointly by the 
International Union Against 
Tuberculosis and Lung 
Disease (The Union) and 
Médecins Sans Frontières 
(MSF). The specific SORT IT 
program which resulted in 
this publication was 
implemented by the Centre 
for Operational Research, 
The Union, Paris, France. 
Mentorship and the 
coordination/facilitation of 
this particular SORT IT 
workshop was provided 
through the Centre for 
Operational Research, The 
Union, Paris, France; the 
Department of Tuberculosis 
and HIV, The Union, Paris, 
France; The Union, 
Zimbabwe Office, Harare, 
Zimbabwe; The Union, 
South East Asia Office, New 
Delhi, India; University of 
Washington, School of Public 
Health, Department of 
Global Health, Seattle, 
Washington, USA; National 
Institute for Medical 
Research, Muhimbili Centre, 
Dar es Salaam, Tanzania; and 
AIDS & TB Department, 
Ministry of Health & Child 
Care, Harare, Zimbabwe.
The training course under 
which this study was 
conducted was funded by 
the UK Department for 
International Development 
(DFID); The Global Fund to 
Fight AIDS, Tuberculosis and 
Malaria (The Global Fund) 
and the World Health 
Organization. The open 
access publications costs 
were funded by DFID, 
London, UK, and La 
Fondation Veuve Emile 
Metz-Tesch, Luxembourg. 
The funders had no role in 
study design, data collection 
and analysis, decision to 
publish, or preparation of the 
manuscript.
Conflicts of interest: none 
declared.
FIGURE The cascade from screening to diagnosis to 
treatment and treatment success in persons screened for 
TB by the mobile Tas4TB programme in Zimbabwe in 
2017. TB = tuberculosis; Tas4TB = targeted active screen-
ing for TB.
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diagnosis of TB, whether bacteriological confirmation or clinical 
diagnosis, registration in the presumptive TB and TB treatment 
registers, and treatment outcomes. Data sources included the 
Tas4TB central electronic database and the presumptive and treat-
ment TB registers. Data were collected in the first quarter of 2019.
Analysis and statistics
Data were captured using EpiData v3.1 (EpiData Association, 
Odense, Denmark), and the data exported to STATA (Stata Corp, 
College Station, TX, USA) for analysis. Frequencies and propor-
tions were used to summarise categorical data. Categorical expo-
sure variables were compared with outcome variables using the χ2 
test and presented as risk ratios (RRs) with 95% confidence inter-
vals (CIs) with respect to treatment outcomes. Levels of signifi-
cance were set at 5% (P  0.05).
Ethics
Ethics approval was obtained from the Zimbabwe Medical Re-
search Council, Harare, Zimbabwe and the Ethics Advisory Group, 
the International Union Against Tuberculosis and Lung Disease, 
Paris, France. Secondary collected data were used, and the ethics 
committees waived the need for patient consent.
RESULTS
The overall flow of patients from being screened to diagnosis to 
treatment and to treatment success is shown in the Figure. More 
details about the screening and TB diagnostic yields are shown in 
Table 1. In total, 663 (1.7%) of 39 065 persons screened were diag-
nosed with TB, with 126 (19%) of these being bacteriologically 
confirmed. Significantly higher TB diagnostic yields were found 
in males, in those aged 65 years and in those categorised in an 
HRG. Just over one third of those screened for TB were in a HRG, 
where the overall TB diagnostic yield (3.2%) was four times 
higher than in the non-HRG group (0.8%). All the different cate-
gories of HRG had significantly higher diagnostic yields com-
pared with the no HRG group, except for health care workers. 
PLHIV had the highest diagnostic yield of 23.8%. There were 126 
(19.0%) diagnosed patients who had bacteriological confirmation 
of TB; this was significantly higher in PLHIV and significantly 
lower in children aged 0–14 years and adults aged 65 years.
There were 14 649 (37%) persons with presumptive TB (12 134 
based on TB symptoms and 2515 based on CXR with no symp-
toms). Of those with positive TB symptoms, 510 (4.2%) were di-
agnosed with TB. Of those with no symptoms but abnormal 
CXRs, 148 (5.9%) were diagnosed with TB (Table 2). The highest 
TB diagnostic yields were in symptomatic persons with a CXR 
suggestive of TB (19.4%), asymptomatic persons with a CXR sug-
gestive of TB (8.4%) and symptomatic persons with an abnormal 
CXR not suggestive of TB (1.7%).
Linkage to care, start of treatment and treatment outcomes are 
shown in Table 3. Overall pre-treatment LTFU was 19%. Overall 
pre-treatment LTFU and treatment outcomes were similar be-
tween symptomatic and asymptomatic TB patients. Pre-treatment 
LTFU was significantly higher, while “not being evaluated” was 
significantly lower in bacteriologically confirmed patients than in 
those with clinically diagnosed TB.
Baseline characteristics associated with pre-treatment LTFU are 
shown in Table 4. There were no significant associations. Of the 
TABLE 1 Characteristics of persons screened and diagnosed with TB by the mobile Tas4TB programme in Zimbabwe in 2017
Characteristics
Screened for TB Diagnosed with TB Bacteriologically confirmed
n n (%)* n (%)†
Total 39 065 663 (1.7) 126 (19.0)
Sex
 Male 14 991 390 (2.6)‡ 77 (19.7)
 Female 24 074 273 (1.1) 49 (17.9)
Age group, years
 0–14 2 605 43 (1.7) 4 (9.3)§
 15–64 31 116 480 (1.5) 110 (22.9)
 65 5 344 140 (2.6)¶ 12 (8.6)¶
HRG
 Yes 14 110 451 (3.2)‡ 94 (20.8)
 No 24 955 212 (0.8) 32 (15.1)
HRGs#
 PLHIV 1 083 258 (23.8)‡ 61 (23.6)§
  PLHIV on ART 921 194 (21.1)¶ 53 (27.3)¶
  PLHIV not on ART 162 64 (40.0)¶ 8 (12.5)
 Miner (formal and informal) 3 439 98 (2.8)‡ 17 (17.3)
 Prison inmate (current and past) 2 077 37 (1.8)‡ 7 (18.9)
 Health care worker 1 652 13 (0.8) 3 (23.1)
 Refugee 268 9 (3.4)‡ 0 —
 Previous TB treatment 2 463 111 (4.5)‡ 18 (16.2)
 TB contact 7 252 157 (2.2)‡ 34 (21.7)
* Denominator = screened for TB.
† Denominator = diagnosed with TB
‡ P  0.001 (comparisons made within groups, except for persons in HRGs, in which case comparisons are made with persons not in an HRG).
§ P  0.05 (comparisons made within groups, except for persons in HRGs, in which case comparisons are made with persons not in an HRG).
¶ P  0.01 (comparisons made within groups, except for persons in HRGs, in which case comparisons are made with persons not in an HRG).
# As some persons belong to two or more of these HRGs, the numbers in HRGs are more than the total shown.
TB = tuberculosis; Tas4TB = targeted active screening for TB; HRG = high-risk group; PLHIV = people living with human immunodeficiency virus; ART = antiretroviral therapy.
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538 TB patients who started treatment, 397 (74%) were success-
fully treated. Baseline characteristics associated with treatment 
success among those who started treatment are shown in Table 5. 
Treatment success was significantly lower in children (56%) than 
in adults, and significantly lower in refugees (33%) than in those 
not belonging to a HRG—this was mainly due to LTFU and not 
being evaluated. Treatment success in miners (87%) was signifi-
cantly higher than those not in a HRG.
DISCUSSION
This is the first reported study on Tas4TB in Zimbabwe, and there 
were some interesting findings. First, Tas4TB had a high TB diag-
nostic yield in the selected districts, at approximately 
1700/100 000, which suggests that ACF can play an important 
role in TB case notification. Although Tas4TB was meant to target 
HRG, nearly two thirds of persons coming for screening were not 
in a HRG. Although case notifications in the non-HRGs were four 
times lower than in HRGs, they were still high and of the order of 
800/100 000.
Second, diagnostic yields in the various HRGs were high and 
similar to those reported elsewhere.5 The high TB diagnostic 
yields in PLHIV, especially those not on antiretroviral therapy, are 
similar to what has been found in other African and Asian coun-
tries undertaking intensified case finding among PLHIV in rou-
tine programme settings,14,15 and the study findings support 
country-wide strategies to actively screen for TB in this group. 
The high diagnostic yields found in patients with previous TB are 
in line with findings in high HIV prevalent areas in sub-Saharan 
Africa,16 although care is needed not to misdiagnose patients who 
may have post-TB chronic lung disease. Why the diagnostic yield 
was not particularly high in health care workers is not clear but 
may be due to their easier access to health care if symptoms de-
velop and less need therefore for Tas4TB services, and also the 
stigma that so often accompanies the disease.
Third, the WHO proposes different options for the use of CXR 
in screening, and recommends that if resources are sufficient CXR 
be performed on everyone reporting for screening.4 Our findings 
support this approach, showing that persons with CXRs sugges-
tive of TB with or without symptoms have a high yield of TB.
Fourth, linkage to care and treatment was sub-optimal, with 
nearly one in five diagnosed patients failing to start treatment. A 
systematic review in Africa, Asia and the Western Pacific found 
that between 4% and 38% of patients with laboratory-confirmed 
TB (based on smear or culture) fail to start treatment.17 This 
pre-treatment LTFU is not reduced with the use of Xpert, with 







Started on anti-tuberculosis treatment
Treatment success* Died LTFU Failed Not evaluated†
n n (%)‡ n (%)‡ n (%)‡ n (%)‡ n (%)‡ n (%)‡
All TB patients 663 125 (19) 397 (60) 23 (3) 26 (4) 0 (0) 92 (14)
With symptoms 510 98 (19) 297 (59) 16 (3) 21 (4) 0 (0) 78 (15)
With no symptoms 153 27 (18) 100 (65) 7 (5) 5 (3) 0 (0) 14 (9)
Bacteriologically 
confirmed 126 35 (28)§ 74 (59) 2 (2) 6 (5) 0 (0) 9 (6)¶
Clinically diagnosed 537 90 (17) 323 (60) 21 (4) 20 (4) 0 (0) 83 (15)
* Treatment success = cured and treatment completed.
† Not evaluated = transferred-out with no outcomes reported and not assessed
‡ Proportion of patients diagnosed with TB.
§ P  0.01, compared with clinically diagnosed TB.
¶ P  0.05, compared with clinically diagnosed TB.
TB = tuberculosis; Tas4TB = targeted active screening for TB; LTFU = loss to follow-up.





Diagnosed with TB Bacteriologically confirmed
n (%)* n (%)†
All persons with TB symptoms 12 134 510 (4.2) 101 (19.8)
 TB symptoms + CXR suggestive of TB‡ 2 432 473 (19.4) 76 (16.1)
 TB symptoms + abnormal CXR not suggestive of TB 593 10 (1.7) 6 (60.0)
 TB symptoms + normal CXR 9 109 27 (0.3) 19 (70.4)
All persons with no TB symptoms 26 931 153 (0.6) 25 (16.3)
 No TB symptoms + CXR suggestive of TB 1 713 144 (8.4) 19 (13.2)
 No TB symptoms + abnormal CXR not suggestive of TB 802 4 (0.5) 3 (0.4)
 No TB symptoms + normal CXR§ 24 416 5 (0.02) 3 (0.01)
* Denominator = screened for TB.
† Denominator = diagnosed with TB.
‡ CXRs were assessed by a medical doctor in the Tas4TB team and were classified into three categories: suggestive of TB; abnormal, not suggestive of TB; and normal.
§ These persons did not fulfil the criteria for TB investigations but they were diagnosed with TB: it is possible that they had forms of extra-pulmonary TB but this was not 
documented.
TB = tuberculosis; CXR = chest radiograph; Tas4TB = targeted active screening for TB.
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TABLE 4 Characteristics associated with pre-treatment LTFU in persons diagnosed with TB by the mobile Tas4TB programme, Zimbabwe, 
2017
Characteristics
Diagnosed with TB Pre-treatment LTFU
RR* (95% CI) P valuen n (%)
Total 663 125 (19)
Sex
 Male 390 77 (20) Reference
 Female 273 48 (18) 0.9 (0.6–1.2) 0.5
Age group, years
 0–14 43 7 (16) 0.9 (0.4–1.7) 0.7
 15–64 480 90 (19) Reference
 65 140 28 (20) 1.1 (0.7–1.6) 0.7
High-risk group
 Yes 451 87 (19) 1.1 (0.8–1.5) 0.7
 No 212 38 (18) Reference
High-risk group†
 PLHIV 258 54 (21) 1.2 (0.8–1.7) 0.4
  PLHIV, on ART 194 42 (22) 1.2 (0.8–1.8) 0.3
  PLHIV, not on ART 64 12 (19) 1.0 (0.6–1.9) 0.9
 Miner (formal and informal) 98 16 (16) 0.9 (0.5–1.6) 0.7
 Prison inmate (current and past) 37 11 (30) 1.7 (0.9–2.9) 0.1
 Health care worker 13 4 (31) 1.7 (0.7–4.0) 0.3
 Refugee 9 0 (0) 0.3 (0.1–4.4) 0.3
 Previous TB 111 28 (25) 1.4 (0.9–2.1) 0.1
 TB contact 157 25 (16) 0.9 (0.6–1.4) 0.6
* Calculated using the non-high-risk group as the reference.
† As some persons appear in two or more of these high-risk groups, the numbers in high-risk groups are more than the total shown.
LTFU = loss to follow up; RR = relative risk; CI = confidence interval; TB = tuberculosis; Tas4TB = targeted active screening for TB; PLHIV = people living with human immunode-
ficiency virus; ART = antiretroviral therapy.
TABLE 5 Characteristics associated with treatment success in TB patients started on treatment as a result of being diagnosed by the mobile 
Tas4TB programme, Zimbabwe, 2017
Characteristics
Started TB treatment Treatment success
RR* (95% CI) P valuen n (%)
Total 538 397 (74)
Sex
 Male 313 227 (73) Reference
 Female 225 170 (76) 1.0 (0.9–1.2) 0.4
Age group, years
 0–14 36 20 (56) 0.7 (0.6–1.0) 0.02
 15–64 390 290 (74) Reference
 65 112 87 (78) 1.1 (0.9–1.2) 0.5
High-risk group
 Yes 364 275 (76) 1.0 (0.9–1.1) 0.6
 No 174 128 (74) Reference
High-risk group†
 PLHIV 204 154 (75) 1.0 (0.9–1.2) 0.7
  PLHIV, on ART 152 116 (76) 1.0 (0.9–1.2) 0.6
  PLHIV, not on ART 52 38 (73) 1.0 (0.8–1.2) 0.9
 Miner (formal and informal) 82 71 (87) 1.2 (1.0–1.3) 0.02
 Prisoner (current and past) 26 19 (73) 1.0 (0.8–1.3) 0.9
 Health care worker 9 5 (56) 0.8 (0.4–1.4) 0.2
 Refugee 9 3 (33) 0.5 (0.2–1.1) 0.01
 Previous TB 83 60 (72) 1.0 (0.8–1.1) 0.8
 TB contact 132 98 (74) 1.0 (0.9–1.2) 0.9
* Calculated using the non-high-risk group as the reference.
† As some persons appear in two or more of these high-risk groups, the numbers in high-risk groups are more than the total shown.
TB = tuberculosis; Tas4TB = targeted active screening for TB; RR = relative risk; CI = confidence interval; PLHIV = people living with human immunodeficiency virus; 
ART = antiretroviral therapy.
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losses varying from 21% in the Cameroon to 45% in South Af-
rica.18,19 A recent study in rural Zimbabwe also showed consider-
able LTFU between screening and diagnosis, and between diagno-
sis and treatment; long distances between rural health centres 
and health facility laboratories and shortage of environmental 
health technicians (who transport sputum specimens from health 
facilities to laboratories) are important contributory factors.20 In 
our study, there were no differences in pre-treatment LTFU be-
tween those with and those without symptoms or between any 
baseline characteristics, but those with bacteriologically con-
firmed TB had higher pre-treatment LTFU than clinically diag-
nosed patients. The reasons are unclear, but bacteriologically con-
firmed TB patients are a risk to the community and they need to 
identified to be treated.
Finally, treatment success was suboptimal. Among all diag-
nosed patients, treatment success was only 60%, and among 
those who started treatment this was 74%, with higher rates in 
miners and lower rates in children and refugees, the latter due to 
high treatment LTFU and not being evaluated. This compares un-
favourably with national treatment success rates, which were re-
ported at 81% for patients with new and relapse TB registered in 
2016.1
The strengths of this study were its implementation in 15 high 
TB burden districts of Zimbabwe, the large number of persons 
screened and the use of the same formal set of questions asked for 
every person screened. The conduct and reporting of the study 
were also in line with the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) guidelines.21 How-
ever, there were some limitations. Important data on time to diag-
nosis and treatment were not obtained and reasons why persons 
without presumptive TB were diagnosed with TB were not 
captured.
There are some important programmatic implications. First, 
the Tas4TB approach identified high numbers of TB cases, al-
though a greater focus on HRGs would increase the yield and 
make the approach more cost-effective. The screening protocol 
includes performing a digital CXR on every person. While TB di-
agnostic yields in non-HRG individuals were high, they were four 
times lower than in HRG individuals, and the justification and 
costs for screening non-HRG individuals should be called into 
question. Second, it is crucial to better understand pre-treatment 
LTFU. This might require prospective research by visiting patients’ 
homes and finding out what has happened. This has been suc-
cessfully done in both Malawi and Zambia, resulting in a better 
understanding of treatment LTFU.22,23 At the same time, measures 
must be put in place to ensure that all diagnosed patients success-
fully start treatment. Third, it is also beholden on the TB pro-
gramme to reduce the proportion of treated patients who are not 
evaluated and thus increase the chance of success. Finally, the da-
tabase needs to be reviewed and modified to capture time to 
event information.
In conclusion, this study has shown that the use of Tas4TB 
(with CXR as part of the screening process) in 15 high-burden dis-
tricts in Zimbabwe resulted in high TB diagnostic yields, which 
was four times higher in persons in HRGs; this calls into question 
whether screening of non-HRG individuals should continue. 
Linkage of diagnosis to care was poor, with one in five patients 
being LTFU before starting treatment; measures to rectify this de-
ficiency should be put in place.
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Contexte  :  Un dépistage actif ciblé de la tuberculose (Tas4TB) à l’aide 
de camions mobiles dans la communauté a été mis en œuvre dans 
15 districts très touchés par la TB au Zimbabwe. La population à 
risque a bénéficié d’un dépistage de TB basé sur les symptômes et la 
radiographie pulmonaire (CXR). Ceux qui ont eu un symptôme 
positif et/ou une anomalie de la CXR ont eu un recueil de crachats 
pour une recherche de TB, un diagnostic et un lien avec la prise en 
charge et le traitement en cas de confirmation de TB.
Objectifs  :  Déterminer 1) la proportion et les caractéristiques des 
patients dépistés ayant eu un diagnostic de TB; 2) la relation entre les 
symptômes de TB et la CXR avec le rendement diagnostique; et 3) la 
mise en route du traitement anti-TB et les résultats du traitement.
Schéma  :  Etude de cohorte basée sur des données recueillies en routine.
Résultats  :  Sur un total de 39 065 personnes dépistées, 663 (1,7%) 
ont eu un diagnostic de TB dont 126 (19,0%) ont été confirmés par 
bactériologie. Le rendement diagnostique de TB a été le plus élevé 
parmi les personnes symptomatiques ayant une CXR suggestive de 
TB (19,4%), parmi les personnes asymptomatique ayant une CXR 
suggestive de TB (8,4%) et parmi les personnes à risque élevé de TB 
(3,2%). Pour tous les patients ayant eu un diagnostic de TB, les pertes 
de vue avant traitement ont été de 18,9% et le succès du traitement 
a été de 59,9%.
Conclusion  :  Tas4TB a abouti à un rendement diagnostique élevé 
mais le lien entre le diagnostic et la prise en charge a été médiocre. 
Les raisons des pertes de vue doivent être mieux comprises et 
rectifiées.
Marco de referencia: En 15 distritos donde la carga de 
morbilidad por tuberculosis (TB) es alta se introdujo la detección 
activa y dirigida de la tuberculosis en unidades móviles (Tas4TB), 
en las comunidades de Zimbabwe. Se practicó el tamizaje de la 
TB en la población con riesgo de contraer la enfermedad 
mediante la interrogación sobre los síntomas indicativos de TB y 
la radiografía de tórax (CXR). En las personas con un tamizaje 
positivo de síntomas, CXR anormal o ambos, se obtuvieron 
muestras de esputo para investigación y diagnóstico y los casos 
diagnosticados se vincularon con los servicios de atención y 
tratamiento.
Objetivo: Determinar la proporción de personas examinadas en 
quienes se diagnosticó la TB y describir sus características; la 
correlación entre los síntomas indicativos de TB y la CXR y el 
rendimiento diagnóstico; y la iniciación del tratamiento 
antituberculoso y los desenlaces terapéuticos.
Método: Fue este un estudio de cohortes a partir de los datos 
corrientes recogidos de manera sistemática.
Resultados: Participaron en el tamizaje 39 065 personas, de las 
cuales 663 recibieron el diagnóstico de TB (1,7%) y se obtuvo la 
confirmación bacteriológica del diagnóstico en 126 casos (19,0%). El 
más alto rendimiento diagnóstico se logró en las personas 
sintomáticas con CXR indicativa de TB (19,4%), las personas 
asintomáticas con CXR indicativa de la enfermedad (8,4%) y las 
personas con riesgo alto de contraer la TB (3,2%). En todos los 
pacientes con diagnóstico de TB, la pérdida de vista antes de iniciar el 
tratamiento fue de 18,9% y el éxito terapéutico se logró en 59,9%.
Conclusión: La detección activa y dirigida de la TB ofreció un alto 
rendimiento diagnóstico, pero la vinculación de las personas con los 
servicios de atención fue deficiente. Es necesario comprender mejor 
las razones de las pérdidas de vista durante el seguimiento y aportar 
soluciones.
